Problem · Life science
Our salesperson cannot hold a conversation with a scientist.
A capable generalist rep, a good script, and a list of principal investigators. Reply rates at a fraction of a percent and the few calls that connect end in 90 seconds, because the rep called a floxed allele a product and the PI heard everything they needed to. Scientific buyers punish generic outreach faster than any market we work in, and the fix is not a better script.
How people search thissales rep does not understand the science · selling to scientists outbound · sdr for life science company · how to sell to principal investigators · technical sales for biotech services
Kinetic at $10,000 a month includes one outbound seat with sequences written in the register of the field, aimed at lab managers and core directors, with a meeting number in writing. Our COO, a molecular biologist with a decade of CRO sales, is on every life science account. Pricing is published.
Why the first sentence decides it
A PI decides whether to reply in the first sentence, and the first sentence has to name the model, the assay, or the phenotype correctly. Volume shops staff for volume, so the caller reads a script written by someone who has never been in a lab. SciLeads' 2026 benchmark puts average cold email reply rate in science sales at 4.2 percent; generic sequences into researchers fall well under 1 percent, and the meetings that do land are with the wrong person.
Aim at the buyer of record, not the famous name
For most purchases under $50,000, the lab manager or core facility director handles vendors and compares quotes; the PI approves. Lab managers read email from vendors because it is their job. PIs delete it because it is not. A sequence to a lab manager that references the lab's last paper and the model it implies gets a reply. Grant timing matters: the months after study section notices are when the money is real.
Let the site do the talking the rep cannot
A researcher who gets a credible first sentence looks you up. If the site carries the targeting strategy, the validation data, the turnaround, and a page for the specific model type, the rep never has to explain the science; the rep has to book the call with the scientist on your side who can. That is the split we run: outbound prospects, qualifies, confirms, and briefs. Your scientist takes the meeting. For one CRO client, the researcher spotlight series plus a sequence to the featured lab and its institution feeds the same calendar as inbound.
Questions on this problem
The same team that wrote your site, reviewed by our COO for register and accuracy. The prospect's diligence confirms the email instead of contradicting it.
Yes, with separate lists, separate sequences, and separate offers per segment. Venture backed biotech prospects get funding and publication triggers; academic accounts get grant timing.
Keep them for the technical conversation. Our seat does the prospecting they hate and books the meetings they want.
George Stoff, Founder and Lead Engineer
Thirty years building software, brands, and demand. On every account.